Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干括派罗欣治疗时存在肝功能失偿死亡风险。

Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).

此外，胰岛抵抗病是慢性丙型肝炎（CHC）中纤维化进展以及对抗病毒治疗无应答的危险因。